Teachers Advisors LLC increased its position in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 25.0% in the third quarter, Holdings Channel reports. The institutional investor owned 210,470 shares of the biopharmaceutical company’s stock after buying an additional 42,091 shares during the period. Teachers Advisors LLC’s holdings in Puma Biotechnology were worth $9,650,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in PBYI. Resources Management Corp CT ADV purchased a new position in Puma Biotechnology during the third quarter worth about $101,000. Macquarie Group Ltd. boosted its holdings in Puma Biotechnology by 37.2% during the third quarter. Macquarie Group Ltd. now owns 648,463 shares of the biopharmaceutical company’s stock worth $29,732,000 after purchasing an additional 175,699 shares during the last quarter. MetLife Investment Advisors LLC boosted its holdings in Puma Biotechnology by 53.0% during the third quarter. MetLife Investment Advisors LLC now owns 21,107 shares of the biopharmaceutical company’s stock worth $968,000 after purchasing an additional 7,316 shares during the last quarter. Sio Capital Management LLC purchased a new position in Puma Biotechnology during the third quarter worth about $1,505,000. Finally, Verition Fund Management LLC purchased a new position in Puma Biotechnology during the third quarter worth about $527,000. 92.10% of the stock is owned by institutional investors and hedge funds.

PBYI has been the topic of several analyst reports. Cantor Fitzgerald boosted their price target on shares of Puma Biotechnology to $55.00 in a report on Tuesday, December 18th. Cowen set a $68.00 price target on shares of Puma Biotechnology and gave the stock a “hold” rating in a report on Friday, November 2nd. Zacks Investment Research cut shares of Puma Biotechnology from a “buy” rating to a “hold” rating in a report on Wednesday, November 14th. Leerink Swann initiated coverage on shares of Puma Biotechnology in a report on Thursday, January 17th. They set a “market perform” rating and a $21.00 price target on the stock. Finally, Guggenheim cut shares of Puma Biotechnology from a “buy” rating to a “neutral” rating in a report on Thursday, January 3rd. Six analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. Puma Biotechnology currently has an average rating of “Hold” and a consensus target price of $58.73.

PBYI stock traded up $0.07 during mid-day trading on Monday, hitting $26.39. The company had a trading volume of 7,426 shares, compared to its average volume of 769,348. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -3.34 and a beta of 0.61. The company has a debt-to-equity ratio of 2.64, a quick ratio of 2.96 and a current ratio of 3.01. Puma Biotechnology Inc has a 12 month low of $17.60 and a 12 month high of $83.15.

In other Puma Biotechnology news, insider Alan H. Auerbach sold 4,424 shares of Puma Biotechnology stock in a transaction dated Thursday, January 3rd. The shares were sold at an average price of $20.67, for a total value of $91,444.08. Following the sale, the insider now owns 31,333 shares of the company’s stock, valued at $647,653.11. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Charles R. Eyler sold 1,239 shares of Puma Biotechnology stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $22.77, for a total transaction of $28,212.03. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,833 shares of company stock worth $347,578. Insiders own 21.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://theolympiareport.com/2019/02/11/teachers-advisors-llc-has-9-65-million-position-in-puma-biotechnology-inc-pbyi.html.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)).

See Also: Fundamental Analysis and Choosing Stocks

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.